3 results
The primary objective is to characterize the change in the Pharmacodynamic (PD) biomarker, fecal calprotectin, during treatment with anrukinzumab.The secondary objectives include:* Characterization of the PK profile and total IL-13 of three multiple…
The main objective of the study is to test if burst SCS is clinically non-inferior to conventional SCS in patients already successfully treated with conventional SCS. The secondary objective of the study is to evaluate patient satisfaction and…
In this non-inferiority study, we aim to identify the diagnostic value of indocyanine green (ICG) fluorescence imaging for SLN mapping versus the standard-of-care 99mTc in the SLN procedure for breast cancer patients.